Mammoth Biosciences announced plans to advance its triglyceride‑lowering gene‑editing program into first‑in‑human testing, revealing nonhuman primate data and plans for an early trial. The company emphasized durable triglyceride reductions in monkey studies and positioned the program as a potentially one‑time genetic treatment for hypertriglyceridemia. A related study presented in Seville suggests patients with preexisting anti‑AAV antibodies may still benefit from liver‑directed gene therapy, challenging the common screening exclusion for many trials. The research offers possible strategies to broaden patient eligibility but highlights the persistent immunological barrier to AAV‑based delivery — a central safety and access concern as more gene editors approach the clinic.